Unknown

Dataset Information

0

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).


ABSTRACT:

Background

We assessed the efficacy and safety of mirabegron, a β3-adrenoceptor agonist, in older adults (≥ 80 years old) with overactive bladder (OAB).

Methods

OAB patients aged ≥ 80 years were enrolled in this prospective, single-arm observational study. OAB was diagnosed based on the OAB symptom score (OABSS); i.e., a total score of ≥ 3 points and an urgency score of ≥ 2 points. Patients who received 50 mg mirabegron once daily were evaluated at the baseline and at 4, 8, and 12 weeks. The changes from the baseline in the OABSS, International Prostate Symptom Score (IPSS), OAB questionnaire (OAB-q) score, and Vulnerable Elders Survey (VES-13) score were determined. Adverse events, laboratory tests, 12-lead electrocardiography, the QT interval according to Fridericia's formula (QTcF), uroflowmetry, the post-void residual urine volume (PVR), and the Mini-Mental State Examination (MMSE) score were used to assess safety.

Results

Forty-three patients (median age: 84 years, range: 80-96 years) were examined. They had high rates of comorbidities and polypharmacy. Mirabegron significantly improved in total score of the OABSS, including urgency and urge incontinence. The total IPSS, IPSS quality-of-life (QOL) index, and OAB-q scores also significantly improved. Mirabegron improved in the VES-13 score. There were no significant changes in laboratory test values, uroflowmetry findings, PVR, the QTcF, or MMSE score. Two patients (4.7%) withdrew from the study after experiencing adverse events.

Conclusions

Mirabegron was well tolerated and significantly improved in OAB symptoms, and QOL in older patients. Trial registration The present clinical study was approved by University of Yamanashi Institutional Review Board prior to study initiation (ID1447) and was retrospectively registered with the UMIN Clinical Trials Registry (UMIN-CTR), Japan (UMIN000045996) on Nov 6, 2021.

SUBMITTER: Nakagomi H 

PROVIDER: S-EPMC8939141 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).

Nakagomi Hiroshi H   Mitsui Takahiko T   Shimura Hiroshi H   Ihara Tatsuya T   Kira Satoru S   Sawada Norifumi N   Takeda Masayuki M  

BMC urology 20220321 1


<h4>Background</h4>We assessed the efficacy and safety of mirabegron, a β<sub>3</sub>-adrenoceptor agonist, in older adults (≥ 80 years old) with overactive bladder (OAB).<h4>Methods</h4>OAB patients aged ≥ 80 years were enrolled in this prospective, single-arm observational study. OAB was diagnosed based on the OAB symptom score (OABSS); i.e., a total score of ≥ 3 points and an urgency score of ≥ 2 points. Patients who received 50 mg mirabegron once daily were evaluated at the baseline and at 4  ...[more]

Similar Datasets

| S-EPMC9826123 | biostudies-literature
| S-EPMC3745617 | biostudies-literature
| S-EPMC4549701 | biostudies-literature
| S-EPMC9972936 | biostudies-literature
| S-EPMC7473960 | biostudies-literature
| S-EPMC10491567 | biostudies-literature
| S-EPMC11840303 | biostudies-literature
| S-EPMC10853986 | biostudies-literature
| S-EPMC4769403 | biostudies-other
| S-EPMC5485167 | biostudies-literature